公开(公告)号：WO2022192370A1

公开(公告)日：2022-09-15

申请号：PCT/US2022/019513

申请日：2022-03-09

申请人： JNANA THERAPEUTICS INC.

发明人： BROWN, Dean, G. ,  HENDERSON, Jaclyn, L. ,  MUNCIPINTO, Giovanni ,  ZWEIG, Joshua, E. ,  NGUYEN, Long, V. ,  PULLEN, Nicholas ,  ANTALEK, Mitchell, T. ,  HOLLIBAUGH, Ryan, A.

IPC分类号： A61K31/429 ,  G01N33/68 ,  A61K31/506

摘要： Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with abnormal levels of amino acids by modulation of SLC6A19 transport.

公开(公告)号：WO2022192139A1

公开(公告)日：2022-09-15

申请号：PCT/US2022/019151

申请日：2022-03-07

申请人： ASTRAZENECA AB ,  MEDIMMUNE, LLC.

发明人： TRAVERS, Jon ,  UROSEVIC DESPOTOVIC, Jelena ,  MOLINA-VILLA, Miguel-Angel ,  BERTRAN-ALAMILLO, Jordi

IPC分类号： A61K31/00 ,  A61K31/517 ,  A61K31/506 ,  A61K45/06 ,  C12N15/00 ,  C12Q1/00 ,  A61P35/00

摘要： Provided are methods for treating cancer with an Aurora kinase B inhibitor comprising determining if a cancer cell has a chromosomal amplification at location 22q11 on chromosome 22. Also provided are methods for treating cancer with an Aurora kinase B inhibitor comprising determining if a cancer cell has a gene with an increased copy number at location 22q11 on chromosome 22. Further provided are methods of determining if a cancer cell or a subject having cancer are amenable to treatment with an Aurora kinase B inhibitor.

公开(公告)号：WO2022190030A1

公开(公告)日：2022-09-15

申请号：PCT/IB2022/052152

申请日：2022-03-10

申请人： AVACA PHARMA PRIVATE LIMITED

发明人： KANDULA, Mahesh

IPC分类号： A61K31/506 ,  A61K31/496 ,  A61K31/135 ,  A61P31/10

摘要： Aspects of the present disclosure provides a topical formulation that includes zinc salt and dexpanthenol or a salt or a hydrate or a solvate thereof. The composition may include one or more other active agents. The compositions of the present disclosure may find utility in treatment of rashes and skin conditions/diseases. Another aspect of the present disclosure provides a method of preparing the topical formulation that includes zinc salt and dexpanthenol or a salt or a hydrate or a solvate thereof.

公开(公告)号：WO2022189618A1

公开(公告)日：2022-09-15

申请号：PCT/EP2022/056316

申请日：2022-03-11

申请人： INSTITUT CURIE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITE PARIS-SACLAY ,  UNIVERSITÉ CLERMONT AUVERGNE

发明人： MEGNIN-CHANET, Frédérique ,  POYER, Florent ,  PIGUEL, Sandrine ,  VERRELLE, Pierre ,  TEULADE-FICHOU, Marie-Paule ,  DEL NERY, Elaine

IPC分类号： A61K31/00 ,  A61K31/4418 ,  A61K31/506 ,  A61K45/06 ,  A61P35/00

摘要： The present invention relates to a compound having the following formula (I), wherein: - R is a group of formula (II) or (III): wherein in particular R1 is H, and Ra and Rb are H; and in particular R2 is H, R4 is H, and R3 is selected from the group consisting of: H, halogen, (C1-C6)alkyl, aryl groups, and heteroaryl groups; - R5 is chosen from the group consisting of: H, (C1-C6)alkyl, and aryl; - i is 1 or 2; and the R7 groups, identical or different, are chosen from the group consisting of: H, halogen, and (C1-C6)alkyl; for use as radiosensitizer.

公开(公告)号：WO2022188889A1

公开(公告)日：2022-09-15

申请号：PCT/CN2022/080732

申请日：2022-03-14

申请人： 杭州英创医药科技有限公司

发明人： 张汉承 ,  贾薇 ,  蔡聪聪

IPC分类号： C07D403/12 ,  C07D401/12 ,  A61P35/00 ,  A61P35/02 ,  A61P9/00 ,  A61P31/12 ,  A61P25/28 ,  A61P29/00 ,  A61K31/506 ,  A61K31/501

摘要： 本发明提供了作为PARP7抑制剂的化合物，具体地，本发明提供了一种如下式(I)所示结构的化合物，或其光学异构体，药学上可接受的盐，前药，氘代衍生物，水合物，溶剂合物。所述的化合物可以用于治疗或预防与PARP7的活性或表达量相关的疾病或病症。

公开(公告)号：WO2022188735A1

公开(公告)日：2022-09-15

申请号：PCT/CN2022/079503

申请日：2022-03-07

申请人： GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD.

发明人： WANG, Zhaoyin ,  SHAO, Yanqiang ,  LI, Lintong ,  LI, Nanxin

IPC分类号： C07D413/04 ,  C07D413/14 ,  C07D239/48 ,  C07D405/12 ,  C07D493/10 ,  C07D491/04 ,  C07D417/14 ,  A61K31/506 ,  A61P35/00

摘要： Provided are heterocyclics as inhibitors of HPK1, in particular a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that is useful for treatment of HPK1 mediated diseases and conditions such as cancer.

公开(公告)号：WO2022185120A1

公开(公告)日：2022-09-09

申请号：PCT/IB2022/000098

申请日：2022-03-04

申请人： NEWAMSTERDAM PHARMA B.V.

发明人： DITMARSCH, Marc ,  KASTELEIN, Johannes Jacob Pieter ,  DAVIDSON, Michael Harvey

IPC分类号： A61K31/506 ,  A61P25/28

摘要： Methods are presented for slowing progression of neurodegenerative disease in a subject who has or is at risk of developing a neurodegenerative disease. The methods comprise administering a therapeutically effective amount of obicetrapib or a pharmaceutically acceptable salt thereof to the subject.

公开(公告)号：WO2022182857A1

公开(公告)日：2022-09-01

申请号：PCT/US2022/017678

申请日：2022-02-24

申请人： IMPACT BIOMEDICINES, INC.

发明人： ARONCHIK, Ida ,  BELTRAN VALENCIA, Roxxana Valeria ,  CARRANCIO ANTON, Maria Soraya ,  CHANG, Henry H. ,  COKER, Shodeinde ,  DAS, Sharmila ,  FILVAROFF, Ellen Hope ,  GUARINOS MARHUENDA, Carla ,  HANNA, Bishoy ,  LIU, Yu ,  NIKOLOVA, Zariana ,  ESPOSITO, Oriana

IPC分类号： A61K31/437 ,  A61K31/506 ,  A61K31/519 ,  A61P35/00

摘要： The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in patients in need thereof. The methods comprise administering to a patient in need a BET (bromodomain and extra-terminal protein) inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with one or more JAK inhibitors. Also provided are medicaments for use in treating cancer.

公开(公告)号：WO2022181763A1

公开(公告)日：2022-09-01

申请号：PCT/JP2022/007866

申请日：2022-02-25

申请人： 学校法人東京理科大学 ,  日本ケミファ株式会社

发明人： 斎藤　顕宜 ,  山田　大輔 ,  中田　恵理子

IPC分类号： A61K45/00 ,  A61P25/00 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P43/00 ,  A61K31/439 ,  A61K31/444 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506

摘要： 本発明は、選択的オピオイドδ受容体アゴニストを有効成分として含み、好ましくは、前記選択的オピオイドδ受容体アゴニストが、更にオピオイドμ受容体アンタゴニスト作用及びオピオイドκ受容体アンタゴニスト作用を有する、ストレス関連障害、ストレス誘発性の不安障害、又はうつ病を併発したストレス関連障害若しくは不安障害の治療又は予防用医薬組成物を提供する。

公开(公告)号：WO2022178224A2

公开(公告)日：2022-08-25

申请号：PCT/US2022/016936

申请日：2022-02-18

申请人： SPINOGENIX, INC.

发明人： SARRAF, Stella T. ,  SIMMON, Vincent F. ,  VANDERKLISH, Peter W.

IPC分类号： A61K31/428 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/00

摘要： In some embodiments, a method of treating spinal cord injury or damage, or a complication thereof, in a patient is provided, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I, Ia, Ik, or II.